

Shirabe K , Toshima T, Taketomi A , Taguchi K, Yoshizumi T, Uchiyama H, Harimoto N, Kajiyama K, Egashira A, Maehara Y.	Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.	Liver Int.	31(9)	1366-72	2011
Taketomi A , Takeishi K, Mano Y, Toshima T, Motomura T, Aishima S, Uchiyama H, Yoshizumi T, Shirabe K , Maehara Y.	Total resection of the right hepatic vein drainage area with the aid of three-dimensional computed tomography.	Surg Today.	42(1)	46-51	2012
Motomura T, Koga E, Taketomi A , Fukuhara T, Mano Y, Muto J, Konishi H, Toshima T, Uchiyama H, Yoshizumi T, Shirabe K , Maehara Y.	Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype.	Hepatol Res.	42(3)	288-95	2012
Taketomi A , Shirabe K , Toshima T, Morita K, Hashimoto N, Kayashima H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y.	The long-term outcomes of patients with hepatocellular carcinoma after living donor liver transplantation: a comparison of right and left lobe grafts.	Surg Today.	42(6)	559-64	2012
Harada N, Shirabe K , Ijichi H, Matono R, Yoshizumi T, Taketomi A , Soejima Y, Maehara Y.	Acoustic radiation force impulse imaging predicts postoperative ascites resulting from curative hepatic resection for hepatocellular carcinoma.	<u>Surgery.</u>	151(6)	837-43	2012
Matono R, Yoshiya S, Motomura T, Toshima T, Kayashima H, Masuda T, Yoshizumi T, Taketomi A , Shirabe K , Maehara Y.	Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.	HPB (Oxford)	14(4)	247-53	2012
*Takeishi K, Taketomi A , Shirabe K , Toshima T, Motomura T, Ikegami T, Yoshizumi T, Sakane F, Maehara Y.	Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.	J Hepatol.	57(1)	77-83	2012

Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Kakisaka T, Tsuruga Y, Todo S, <u>Taketomi A.</u>	Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.	World J Surg Oncol			2012
Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi <u>M, Natsuizaka M,</u> Suda G, ho T, Hatanaka K, Matsuno Y, Yokoo H, Kamiyama T, <u>Taketomi A,</u> Fujii G, Tashiro K, Hikiba Y, Fujimoto M, Asaka M, Maeda S.	Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor- κ B/mitogen-activated protein kinase.	Carcinogenesis.	35(2)	272-81	2014
Honda S, Miyagi H, Suzuki H, Minato M, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, Okada T, <u>Taketomi A.</u>	RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.	Pediatr Surg Int.	29(11)	1147-52	2013
Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, <u>Taketomi A.</u>	Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium.	World J Surg Oncol.			2013
Shibasaki S, Takahashi N, Toi H, Tsuda I, Nakamura T, Hase T, Minagawa N, Homma S, Kawamura H, <u>Taketomi A.</u>	Percutaneous transhepatic gallbladder drainage followed by elective laparoscopic cholecystectomy in patients with moderate acute cholecystitis under antithrombotic therapy.	J Hepatobiliary Pancreat			2013
Okada T, Honda S, Miyagi H, Kubota KC, Cho K, <u>Taketomi A.</u>	Liver fibrosis in prenatally diagnosed choledochal cysts.	J Pediatr Gastroenterol Nutr.	57(2)		2013
Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y, Fujiyoshi M, <u>Taketomi A,</u> Nishimura S, Todo S.	Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis.	Hepatology.	57(6)	2314-25	2013

Shirabe K , Motomura T, Takeishi K, Morita K, Kayashima H, Taketomi A , Ikegami T, Soejima Y, Yoshizumi T, Maehara Y.	Human early liver regeneration after hepatectomy in patients with hepatocellular carcinoma: special reference to age.	Scand J Surg.	102(2)	101-5	2013
Ijichi H, Shirabe K , Taketomi A , Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y.	Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma.	Hepatology Res.	43(5)	481-7	2013
Shimada S, Kamiyama T, Yokoo H, Wakayama K, Tsuruga Y, Kakisaka T, Kamachi H, Taketomi A .	Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma.	World J Surg Oncol.			2013
Taketomi A , Shirabe K , Muto J, Yoshiya S, Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K, Maehara Y.	A rare point mutation in the Ras oncogene in hepatocellular carcinoma.	Surg Today	43(3)	289-92	2013
Mano Y, Aishima S, Fujita N, Tanaka Y , Kubo Y, Motomura T, Taketomi A , Shirabe K , Maehara Y, Oda Y.	Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma.	Pathobiology.	80(3)	146-54	2013
* Kurosaki M , Tsuchiya K, Nakanishi H, Itakura J, Izumi N.	Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy.	Journal of Gastroenterology	48	777-778	2013
*Tomiya Y, Nishina S, Hara Y, Kawase T, Hino K	Hepatic oxidative stress in ovariectomized transgenic mice expressing the hepatitis C virus polyprotein is augmented through suppression of AMPK/PGC-1alpha signaling	Hepatology Res	DOI: 10.1111/hepr.12254		2013

Hino K , Hara Y, Nishina S	Mitochondrial reactive oxygen species as a mystery voice in hepatitis C	Hepatol Res		DOI: 10.1111/hepr.12247	2013
Hino K , Nishina S, Hara Y	Iron metabolic disorder in chronic hepatitis C: Mechanisms and relevance to hepatocarcinogenesis	J Gastroenterol Hepatol	28 Suppl 4	1993/8/1	2013
Tomiyama Y, Takenaka K, Kodama T, Kawanaka M, sasaki K, Nishina S, Yoshioka N, Hara Y, Hino K	Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis	Intern Med	52	1553-9	2013
Korenaga K, Korenaga M, Teramoto F, Suzuki T, Nishina S, Sasaki K, Nakashima Y, Tomiyama Y, Yoshioka N, Hara Y, Moriya T, Hino K	Clinical usefulness of non-protein respiratory quotient measurement in non-alcoholic fatty liver disease	Hepatol Res	43	1284-94	2013
Nakamura M, Nakashima H, Tsutsumi K, Matsumoto H, Muta Y, Ueno D, Yoshida K, Hino K , Urakami A, Tanaka M	First jejunal vein oriented mesenteric excision for pancreatoduodenectomy	J Gastroenterol	48	989-95	2013
Kawanaka M, Nishino K, Suehiro M, Goto D, Urata N, Oka T, Kawamoto H, Nakamura H, Yodoi J, Hino K , Yamada G	Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study	Hepatic Medicine: Evidence and Research	5	11-16	2013
Natsuizaka M , Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, Chang S, Nakagawa KJ, Rustgi NL, Kita Y, Natsugoe S, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Rustgil AK, Nakagawa H.	IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment.	Am J Cancer Res	4(1)	29	2014
Ijichi H, Yoshizumi T, Ikegami T, Soejima Y, Ikeda T, Kawanaka H, Uchiyama H, Yamashita Y, Morita M, Oki E, Mimori K, Sugimachi K, Saeki H, Watanabe M, Shirabe K , Maehara Y	Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.	Fukuoka Igaku Zasshi.	104 (10)	376-82	2013

Zhang B, Jia WH, Matsuo K, Shin A, Xiang YB, Matsuda K , Jee SH, Kim DH, Cheah PY, Ren Z, Cai Q, Long J, Shi J, Wen W, Yang G, Ji BT, Pan ZZ, Matsuda F, Gao YT, Oh JH, Ahn YO, Kubo M, Thean LF, Park EJ, Li HL, Park JW, Jo J, Jeong JY, Hosono S, Nakamura Y, Shu XO, Zeng YX, Zheng W.	Genome-wide association study identifies a new SMAD7 risk variant associated with colorectal cancer risk in East Asians.	Int J Cancer.	doi: 10.1002/ijc.28733.		2014 [Epub ahead of print]
*Lo PH, Urabe Y, Kumar V, Tanikawa C, Koike K , Kato N, Miki D, Chayama K, Kubo M, Nakamura Y, Matsuda K .	Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.	PLoS One.	8(4)	e61279	2013
Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PH, Tanikawa C, Omata M, Koike K , Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, Chayama K, Nakamura Y, Matsuda K .	A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region.	J Hepatol.	58(5)	875-82.	2013
Tanikawa C, Matsuo K, Kubo M, Takahashi A, Ito H, Tanaka H, Yatabe Y, Yamao K, Kamatani N, Tajima K, Nakamura Y, Matsuda K .	Impact of PSCA variation on gastric ulcer susceptibility.	Plos one	8(5)	E63698	2013
Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators, Kubo M, Matsuda K , Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.	Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.	Clin Cancer Res.	19(23)	6430-7	2013
*Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, Nomura Y, Yoshida M, Hayashi T, Oishi N, Ikeda H, Honda M , Kaneko S.	The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.	J Hepatol	60(1)	127-134	2014

<p>Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato KI, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, Arai K, Yamashita T, Mizukoshi E, Kaneko S.</p>	<p>The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.</p>	<p>Diabetologia</p>	<p>in press</p>		<p>2014</p>
<p>Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S.</p>	<p>Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes.</p>	<p>Hepatology</p>	<p>in press</p>		<p>2013</p>
<p>Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S.</p>	<p>Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.</p>	<p>Hepatology Res</p>	<p>in press</p>		<p>2013</p>
<p>Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, Lanford RE, Lemon SM.</p>	<p>MicroRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection.</p>	<p>PLoS One</p>	<p>in press</p>		<p>2013</p>
<p>Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S.</p>	<p>Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma.</p>	<p>BMC Cancer</p>	<p>in press</p>		<p>2013</p>
<p>Miyahara K, Nouse K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group.</p>	<p>Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.</p>	<p>Br J Cancer</p>	<p>109(8)</p>	<p>2072-2078</p>	<p>2013</p>
<p>Higashimoto M, Sakai Y, Takamura M, Usui S, Nasti A, Yoshida K, Seki A, Komura T, Honda M, Wada T, Furuichi K, Ochiya T, Kaneko S.</p>	<p>Adipose tissue derived stromal stem cell therapy in murine ConA-derived hepatitis is dependent on myeloid-lineage and CD4+ T-cell suppression.</p>	<p>Eur J Immunol</p>	<p>43(11)</p>	<p>2956-2968</p>	<p>2013</p>

Seki A, Sakai Y, Komura T, Nasti A, Yoshida K, Higashimoto M, <u>Honda M</u> , Usui S, Takamura M, Takamura T, Ochiya T, Furuichi K, Wada T, Kaneko S.	Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model.	Hepatology	58(3)	1133-142	2013
Komura T, Sakai Y, <u>Honda M</u> , Takamura T, Wada T, Kaneko S.	ER stress induced impaired TLR signaling and macrophage differentiation of human monocytes.	Cell Immunol	282(1)	44-52	2013
Shirasaki T, <u>Honda M</u> , Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S.	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	J Virol	87(9)	5270-5286	2013
Hodo Y, <u>Honda M</u> , Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S.	Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C.	Clin Cancer Res	19(7)	1827-1837	2013
Yamashita T, <u>Honda M</u> , Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S.	Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.	Hepatology	57(4)	1484-1497	2013
Nishino J, <u>Mano S</u>	The Number of Candidate Variants in Exome Sequencing for Mendelian Disease under No Genetic Heterogeneity	Computational and Mathematical Methods in Medicine	2013	179761-179771. 13pp.	2013
間野修平	ポストゲノム時代に遺伝疫学を考える	生物の科学「遺伝」	67(3)	368-371	2013
Jo Nishino, Masaya Sugiyama, <u>Nao Nishida</u> , <u>Katsushi Tokunaga</u> , <u>Masashi Mizokami</u> , <u>Shuhei Mano</u>	The SNP × age interaction on response to interferon- α and ribavirin therapy in hepatitis C woman patients	Journal of Medical Virology		in press	
Ahn S, Tamai M, Nakashima K, Ito M, <u>Suzuki T</u> , Tagawa Y.	An in vitro liver model consisting of endothelial vascular networks surrounded by human hepatoma cell lines allows for improved hepatitis B virus replication.	J Biosci. Bioeng.		in press	2014

*Posuwan N, Payungporn S, Tangkijvanich P, Ogawa S, Murakami S, Iijima S, Matsuura K, Shinkai N, Watanabe T, Poovorawan Y, Tanaka Y.	Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population.	PLoS One.	9(1)	e86007	
Elkady A, Aboulfotuh S, Ali EM, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Iijima S, Tanaka Y.	Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.	World J Gastroenterol.	19(37)	6214-20	

*研究成果の別刷あり

IV. 研究成果の刊行物・別刷

Genome-wide association study identified *ITPA/DDRKG1* variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

Yasuhito Tanaka^{1,2,†}, Masayuki Kurosaki^{3,†}, Nao Nishida⁴, Masaya Sugiyama^{1,2,5}, Kentaro Matsuura^{1,6}, Naoya Sakamoto⁷, Nobuyuki Enomoto⁸, Hiroshi Yatsushashi⁹, Shuheh Nishiguchi¹⁰, Keisuke Hino¹¹, Shuheh Hige¹², Yoshito Itoh¹³, Eiji Tanaka¹⁴, Satoshi Mochida¹⁵, Masao Honda¹⁶, Yoichi Hiasa¹⁷, Asako Koike¹⁸, Fuminaka Sugauchi^{1,6}, Shuichi Kaneko¹⁶, Namiki Izumi³, Katsushi Tokunaga⁴ and Masashi Mizokami^{5,*}

¹Department of Virology and ²Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan, ⁴Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁵The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan, ⁶Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁷Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁸First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan, ⁹Clinical Research Center, National Nagasaki Medical Center, Nagasaki, Japan, ¹⁰Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ¹¹Division of Hepatology and Pancreatology, Kawasaki Medical College, Kurashiki, Japan, ¹²Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ¹³Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁴Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan, ¹⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan, ¹⁶Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ¹⁷Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Ehime, Japan, and ¹⁸Central Research Laboratory, Hitachi Ltd, Kokubunji, Japan

Received February 9, 2011; Revised May 16, 2011; Accepted May 31, 2011

Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. The aim of this study was to identify host factors associated with IFN-induced thrombocytopenia by genome-wide association study (GWAS). In the GWAS stage using 900K single-nucleotide polymorphism (SNP) microarrays, 303 Japanese CHC patients treated with PEG-IFN/RBV therapy were genotyped. One SNP (rs11697186) located on *DDRKG1* gene on chromosome 20 showed strong associations in the minor-allele-dominant model with the decrease of platelet counts in response to PEG-IFN/RBV therapy [$P = 8.17 \times 10^{-9}$; odds ratio (OR) = 4.6]. These associations were replicated in another sample set ($n = 391$) and the combined P -values reached 5.29×10^{-17} (OR = 4.5). Fine mapping with 22 SNPs around *DDRKG1* and *ITPA* genes showed that rs11697186 at the GWAS stage had a strong linkage disequilibrium with rs1127354, known as a functional variant in the *ITPA* gene. The

*To whom correspondence should be addressed at: The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan. Tel: +81 473723501; Fax: +81 473754766; Email: mmizokami@hospk.ncgm.go.jp
[†]These authors contributed equally.

***ITPA*-AA/CA genotype was independently associated with a higher degree of reduction in platelet counts at week 4 ($P < 0.0001$), as well as protection against the reduction in hemoglobin, whereas the CC genotype had significantly less reduction in the mean platelet counts compared with the AA/CA genotype ($P < 0.0001$ for weeks 2, 4, 8, 12), due to a reactive increase of the platelet count through weeks 1–4. Our present results may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN/RBV dosing to minimize drug-induced adverse events.**

INTRODUCTION

Chronic infection with hepatitis C virus (HCV) presents a significant health problem worldwide, with ~2.3% of the world population, i.e. more than 120–130 million people, being infected (1). Only 20–30% of HCV-infected individuals recover spontaneously. The remaining 70–80% go on to develop chronic infection, being at significant risk for progressive liver fibrosis and subsequent liver cirrhosis (LC) and hepatocellular carcinomas (HCC). Successful treatment of chronic hepatitis C (CHC) leads to a reduction of liver fibrosis stage of patients, and also prevents HCC development (2).

Antiviral treatment has been shown to improve liver histology and decrease incidence of hepatocellular carcinoma in CHC (3,4). Current therapy for CHC consists of treatment with pegylated interferon (IFN), which acts both as an antiviral and as an immunoregulatory cytokine, and ribavirin (RBV), an antiviral pro-drug that interferes with RNA metabolism (5,6). However, <50% of patients infected with HCV genotype 1 treated in this way achieve a sustained viral response (SVR) or cure of the infection (5,7). Older patients with liver fibrosis showed a significantly lower SVR rate due to poor adherence resulting from adverse events and laboratory abnormalities (8–10). In particular, hematologic abnormalities often necessitate dose reduction, and premature withdrawal from therapy in 10–14% of patients (5,11–14). New drugs and therapeutic approaches for CHC are actively developed and several candidates are in early trial phase (15,16). Given this background, effective pre-treatment screening for predictive biomarkers with the aim of evaluating possible risks over benefits of currently available treatment will avoid these side effects in patients who will not be helped by treatment, as well as reduce the substantial cost of treatment.

The completion of the Human Genome Project has led to the advent of a new era of scientific research, including a revolutionary approach: the genome-wide association study (GWAS). Several recent studies, including our study, have demonstrated marked associations between single-nucleotide polymorphisms (SNPs) within and around *IL28B* gene, which codes for IFN- λ 3 (16–21). Another recent study indicated that genetic variants of *ITPA* gene leading to inosine triphosphatase (*ITPA*) deficiency could protect against hemolytic anemia (HA) in CHC patients receiving RBV (22).

In Japan, HCV-infected patients are relatively old and some of them have had severe fibrosis (9). Thrombocytopenia is one of the critical adverse events by IFN-based therapy among liver cirrhotic patients (23), because low platelet count (PLT), i.e. <30.0 ($10^9/l$), would be a risk factor for any bleeding, as well as it would lead to poor treatment efficiency due to the initial or early dose reduction of PEG-IFN. Based on its pathogenesis, drug-induced thrombocytopenia is usually due to bone marrow

suppression, immune-mediated destruction and platelet aggregation (24). In this study, we firstly found that genetic variants in the *ITPA/DDRGK1* genes were associated with IFN-induced thrombocytopenia, and then examined the correlation between IFN-induced thrombocytopenia and RBV-induced HA in Japanese CHC patients under PEG-IFN/RBV treatment.

RESULTS

Genetic variants associated with IFN-induced thrombocytopenia

In this study, we conducted a GWAS to identify host genes associated with the decrease of platelets in response to PEG-IFN/RBV treatment in 303 Japanese HCV patients (107 patients with the decrease of PLT versus 196 patients without the decrease of PLT based on the criteria described in Materials and Methods), using a genome-wide SNP typing array (Affymetrix SNP 6.0 for 900K SNPs). The characteristics of patients for each GWAS stage and replication stage are summarized in Table 1. Figure 1 shows a genome-wide view of the single-point association data based on allele frequencies. One SNP (rs11697186) located on *DDRGK1* gene on chromosome 20 showed strong associations in the allele frequency model ($P = 8.17 \times 10^{-9}$) with the decrease of PLT in response to PEG-IFN plus RBV treatment. The association reached genome-wide level of significance [Bonferroni criterion $P < 8.40 \times 10^{-8}$ (0.05/595052)], and another SNP (rs6139030) near *ITPA* gene had a marginal significance ($P = 4.30 \times 10^{-7}$, in Table 2).

To validate the results of the GWAS stage, 22 SNPs were selected for the replication in a set of 391 Japanese HCV patients with and without platelet reduction (Supplementary Material, Table S1). The associations of the original significant SNP (rs11697186) and the marginal SNP (rs6139030) at the GWAS stage were replicated in the second set of 391 patients in the minor-allele-dominant model [$P = 5.88 \times 10^{-10}$, odds ratio (OR) = 4.6 for rs11697186; $P = 3.83 \times 10^{-10}$, OR = 4.3 for rs6139030, Table 2]. The combined P -values for both stages reached 5.29×10^{-17} (OR = 4.5; 95% CI = 3.1–6.5) and 1.33×10^{-15} (OR = 3.9; 95% CI = 2.8–5.5), respectively (Table 2).

Genetic variants associated with RBV-induced anemia

We also conducted a GWAS to identify host genes associated with a quantitative change in hemoglobin (Hb) levels from baseline to week 4 of PEG-IFN/RBV treatment in the above 303 Japanese HCV patients (94 patients with an Hb reduction of ≥ 3 g/dl at week 4 and 209 patients without Hb reduction), using a genome-wide SNP typing array (Affymetrix SNP 6.0 for 900K SNPs). Two SNPs (rs11697186 and rs6139030)

Table 1. Clinical characteristics of patients in this study

	GWAS (<i>n</i> = 303)	Replication (<i>n</i> = 391)
Age	57.4 (9.7)	56.8 (9.9)
Sex (M/F)	151/152	209/182
Weight (kg)	60.6 (10.4)	61.3 (10.7)
Body mass index	23.5 (3.1)	23.7 (4.1)
Baseline Hb (g/dl)	14.1 (1.4)	14.1 (1.4)
Baseline platelet count (10 ⁹ /l)	151.3 (54.3)	159.7 (55.0)
Baseline ALT (IU/l)	83.5 (79.4)	86.8 (71.9)
Baseline creatinine (mg/dl)	0.70 (0.15)	0.72 (0.16)
Baseline liver fibrosis (F0–2/F3–4/ND)	153/77/73	175/59/43
rs8099917: TT/non-TT	165/138	296/95
rs1127354: AA/CA/CC	4/79/220	6/101/284
Week 4 Hb (g/dl)	11.8 (1.7)	11.9 (1.5)
Week 4 platelet count (10 ⁹ /l)	127.6 (48.2)	132.4 (51.0)
Hb reduction at week 4	–2.3 (1.4)	–2.2 (1.4)
Platelet reduction at week 4	–22.2 (38.4)	–24.7 (30.4)

located on *DDRGK1* gene and *ITPA* gene on chromosome 20 showed strong associations in the allele frequency model ($P = 3.29 \times 10^{-10}$ and $P = 2.56 \times 10^{-9}$) with Hb reduction in response to PEG-IFN plus RBV treatment (Table 3).

The above 22 SNPs were selected for the replication study and fine mapping, including rs1127354, which was reported by the US group (22) to be strongly associated with Hb reduction (Supplementary Material, Table S2). All SNPs were genotyped using the DigiTag2 assay in an independent set of 391 Japanese HCV patients with quantitative change in Hb in response to PEG-IFN/RBV treatment [137 patients with Hb reduction versus 254 patients without Hb reduction (Table 3)]. The associations of the original SNPs were replicated in the second set of 391 patients in the minor-allele-dominant model ($P = 3.86 \times 10^{-16}$, OR = 0.02 for rs11697186; $P = 6.90 \times 10^{-18}$, OR = 0.03 for rs6139030, Table 3). The combined P -values for both stages reached 9.43×10^{-25} (OR = 0.03; 95% CI = 0.01–0.08) and 2.12×10^{-25} (OR = 0.04; 95% CI = 0.02–0.09), respectively (Table 3). The rs1127354 was also strongly associated with a quantitative change in Hb in response to PEG-IFN/RBV treatment in a set of 694 Japanese HCV patients (303 patients from the GWAS stage plus the second set of 391 patients) with and without Hb reduction ($P = 4.58 \times 10^{-26}$, OR = 0.03; 95% CI = 0.01–0.08).

Fine mapping with 22 SNPs around *DDRGK1* and *ITPA* genes showed that four significant SNPs (rs11697186, rs6139030, rs1127354 and rs13830) at the GWAS stage had a strong linkage disequilibrium (LD) ($r^2 > 0.86$) within the 22.7 kb region (Fig. 2). As the rs1127354 is known as a functional variant in the *ITPA* gene that caused ITPase deficiency and protected against RBV-induced HA (22,25), the representative SNP was applied for the following detailed studies.

***ITPA/DDRGK1* variants reflect anemia and reactive increase of the platelet count**

The mean quantitative reduction of blood cells from the baseline according to the *ITPA* rs1127354 genotypes is shown in Figure 3. Patients with the rs1127354 genotypes AA and CA showed lower degree of Hb reduction at weeks 2, 4, 8 and

12 during therapy compared with those with the CC genotype ($P < 0.0001$ for weeks 2, 4, 8 and 12 in Fig. 3A). The most difference of mean Hb reduction was found at week 4 (AA/CA –1.14 versus CC –2.72). These results show that the AA and CA genotypes are significantly associated with less absolute reduction in Hb levels, especially during the early weeks of therapy, and protect against the development of severe anemia. Interestingly, the CC genotype had significantly less reduction in the mean platelet count compared with the AA/CA genotype ($P < 0.0001$ for weeks 2, 4, 8; $P = 0.019$ for week 12 in Fig. 3B), due to a reactive increase of platelet count through weeks 1–4. The most difference of mean platelet reduction was found at week 4 [AA/CA –41.2 versus CC –18.0 (10⁹/l)]. There was no difference in the neutrophil leukocyte count between genotypes (Fig. 3C). We then compared the percentage of patients with platelet count reduction in the *ITPA* rs1127354 genotypes at week 4 of PEG-IFN/RBV therapy (Fig. 4). The percentage of patients with a platelet count reduction of <30 (10⁹/l) at week 4 was significantly higher in the rs1127354 genotypes CC ($P < 0.0001$), indicating that the degree of platelet count reduction was less in patients with the rs1127354 genotype CC. A multivariate analysis for factors associated with a platelet reduction >30 (10⁹/l) at week 4 showed that lower platelet count at the baseline and the rs1127354 genotypes AA/CA were independently associated with platelet reduction (OR = 1.15; 95% CI = 1.11–1.20; $P < 0.0001$, OR = 5.92; 95% CI = 3.82–9.17; $P < 0.0001$, respectively).

Figure 5 showed reactive increase of the platelet count through weeks 1–4 of PEG-IFN/RBV therapy. Patients with anemia (Hb reduction ≥ 3.0 g/dl) at week 4 had a significantly higher degree of the reactive increase of the platelet count than those without anemia ($P < 0.0001$ in Fig. 5A). Within a subgroup of patients with the rs1127354 genotypes CC, patients with anemia still had a significantly higher degree of reactive increase of the platelet count than those without anemia ($P = 0.004$ in Fig. 5B). On the other hand, patients with the rs1127354 genotypes CC had a significantly higher degree of the reactive increase of the platelet count than those with genotypes AA/CA ($P < 0.0001$ in Fig. 5C), and a similar result was obtained in a subgroup of patients without anemia (Fig. 5D). To elucidate the significant factors associated with the rs1127354 genotypes by multivariate analysis, the rs1127354 genotypes AA/CA were independently associated with protection against the reduction in Hb and more reduction in platelet counts at week 4 due to a lower degree of the reactive increase of the platelet count (OR = 0.029; 95% CI = 0.009–0.092; $P < 0.0001$, OR = 4.73; 95% CI = 3.04–7.37; $P < 0.0001$, respectively). Indeed, the reactive increase of the platelet count through weeks 1–4 was positively correlated with a high platelet count at the baseline and anemia (Hb reduction ≥ 3.0 g/dl) at week 4, but was negatively correlated with rs1127354 genotypes AA/CA and a platelet count reduction of ≥ 30 (10⁹/l) at week 4 (Table 4).

Relationship between *ITPA* rs1127354 genotypes and treatment outcome due to dose reduction of PEG-IFN or RBV

In this population, a multivariate analysis showed that SVR was significantly associated with *IL28B* TT-genotype [OR




Figure 1. Genome-wide association results in 303 Japanese HCV patients with the decrease of platelets in response to PEG-IFN plus RBV treatment (107 patients with the decrease of PLT and 196 patients without the decrease of PLT). P -values were calculated using the χ^2 test for allele frequencies. Dots with arrow on chromosome 20 showed a significant SNP ($P = 8.17 \times 10^{-9}$ for rs11697186) and a candidate SNP with a marginal significance ($P = 4.30 \times 10^{-7}$ for rs6139030) associated with the decrease of PLT with response to PEG-IFN/RBV treatment. The dotted line indicates a genome-wide significance ($P < 8.40 \times 10^{-8}$).

Table 2. Two SNPs (rs11697186 and rs6139030) significantly associated with the decrease of PLT in response to PEG-IFN/RBV treatment

dbSNP rsID	Nearest gene	MAF ^a (allele)	Allele (1/2)	Stage	Patients with the decrease of PLT			Patients without the decrease of PLT			OR (95% CI) ^b	P -value ^c
					11	12	22	11	12	22		
rs11697186	<i>DDRGKI</i>	0.15 (T)	T/A	GWAS	3 (2.8)	48 (44.9)	56 (52.3)	0 (0.0)	32 (16.6)	161 (83.4)	4.6 (2.7–7.8)	8.17×10^{-9}
				Replication	3 (1.8)	65 (39.9)	95 (58.3)	3 (1.4)	25 (12.0)	181 (86.6)	4.6 (2.8–7.7)	5.88×10^{-10}
				Combined	6 (2.2)	113 (41.9)	151 (55.9)	3 (0.7)	57 (14.2)	342 (85.1)	4.5 (3.1–6.5)	5.29×10^{-17}
rs6139030	<i>ITPA</i>	0.17 (C)	T/C	GWAS	56 (52.3)	48 (44.9)	3 (2.8)	157 (80.1)	38 (19.4)	1 (0.5)	3.7 (2.2–6.1)	4.30×10^{-7}
				Replication	96 (54.9)	74 (42.3)	5 (2.9)	181 (83.8)	32 (14.8)	3 (1.4)	4.3 (2.7–6.8)	3.83×10^{-10}
				Combined	152 (53.9)	122 (43.3)	8 (2.8)	338 (82.0)	70 (17.0)	4 (1.0)	3.9 (2.8–5.5)	1.33×10^{-15}

^aMinor allele frequency and minor allele in 184 healthy Japanese individuals.

^bOR for the minor allele in a dominant model.

^c P -value by χ^2 test for the minor allele dominant model.

6.12 (2.78–13.46), $P < 0.0001$] as well as platelet counts [OR 1.18 (1.11–1.26), $P < 0.00001$]. We analyzed whether the rs1127354 genotype could influence the treatment outcome by PEG-IFN/RBV therapy. When analyzed in the patients available for treatment outcome (172 with *ITPA*-AA/CA and 450 with *ITPA*-CC), the percentage of patients receiving $>80\%$ of the expected PEG-IFN and RBV dose at baseline and week 4 was not significantly different among the rs1127354 genotypes. However, the rate of SVR tended to be higher in patients with *ITPA*-AA/CA genotype than those with *ITPA*-CC (48.8 versus 37.3%), because the relapse rate was lower in patients with *ITPA*-AA/CA. To investigate the influence on treatment outcome by dose reduction of PEG-IFN, in a subgroup of patients with low platelet counts (<10) at baseline (19 with *ITPA*-AA/CA and 53 with *ITPA*-CC) we analyzed the treatment outcome according to

rs1127354 genotypes. The SVR rate was very low in each group (21.1% in *ITPA*-AA/CA and 17.0% in *ITPA*-CC), because many patients had the initial dose reduction of PEG-IFN ($<80\%$ of standard dose)—36.8% of patients with *ITPA*-AA/CA and 44.6% of patients with *ITPA*-CC genotype. Further prospective studies are required among the pre-cirrhotic or cirrhotic patients with low platelet counts.

DISCUSSION

Recent genome-wide association studies, including our study on HCV infection, have identified two important host genetic variants: the SNP in *IL28B* gene, which is strongly associated with response to therapy for chronic genotype 1 HCV infection (16–21), and the SNP in *ITPA* gene, which precisely predicts RBV-induced anemia in

Table 3. Two SNPs (rs11697186 and rs6139030) significantly associated with quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment

dbSNP rsID	Nearest gene	MAF ^a (allele)	Allele (1/2)	Stage	Patients with quantitative change in Hb			Patients without quantitative change in Hb			OR (95% CI) ^b	P-value ^c
					11	12	22	11	12	22		
rs11697186	<i>DDRGK1</i>	0.15 (T)	T/A	GWAS	0 (0.0)	3 (3.3)	89 (96.7)	3 (1.5)	77 (37.0)	128 (61.5)	0.06 (0.02–0.16)	3.29×10^{-10}
					0 (0.0)	2 (1.5)	134 (98.5)	6 (2.5)	88 (37.3)	142 (60.2)	0.02 (0.01–0.09)	3.86×10^{-16}
					0 (0.0)	5 (2.2)	223 (97.8)	9 (2.0)	165 (37.2)	270 (60.8)	0.03 (0.01–0.08)	9.43×10^{-25}
rs6139030	<i>ITPA</i>	0.17 (C)	T/C	GWAS	88 (93.6)	6 (6.4)	0 (0.0)	125 (59.8)	80 (38.3)	4 (1.9)	0.08 (0.03–0.22)	2.56×10^{-9}
					134 (97.8)	3 (2.2)	0 (0.0)	143 (56.3)	103 (40.6)	8 (3.1)	0.03 (0.01–0.08)	6.90×10^{-18}
					222 (96.1)	9 (3.9)	0 (0.0)	268 (57.9)	183 (39.5)	12 (2.6)	0.04 (0.02–0.09)	2.12×10^{-25}

^aMinor allele frequency and minor allele in 184 healthy Japanese individuals.

^bOR for the minor allele in a dominant model.

^cP-value by χ^2 square test for the minor allele dominant model.




Figure 2. Pairwise LD (r^2) diagrams for *DDRGK1* and *ITPA*. Lower panel shows estimates of pairwise r^2 for 22 SNPs selected in the replication study using the second set of 391 Japanese HCV patients with and without quantitative change in PLT levels from baseline to week 4 of PEG-IFN/RBV treatment.

European-American population (22) and Japanese population (26). The genetic variation of *ITPA* causing an accumulation of inosine triphosphate (ITP) has been shown to protect patients against RBV-induced anemia during treatment for

CHC infection. A recent report showed the biologic mechanism that ITP confers protection against RBV-induced ATP reduction by substituting for erythrocyte GTP, which is depleted by RBV, in the biosynthesis of ATP (25).




Figure 3. *ITPA* rs1127354 genotypes and the quantitative reduction of blood cells from baseline. Mean reduction of (A) Hb levels, (B) platelet counts and (C) neutrophil leukocyte counts during treatment according to rs1127354 genotype is shown. Solid and dotted lines indicate patients with CC and AA/CA genotypes, respectively. Error bars indicate standard error. CC genotype had more reduction in mean Hb levels during therapy compared with the AA/CA genotype (* $P < 0.0001$ for weeks 2, 4, 8, 12). CC genotype had less of a reduction in mean platelet counts (* $P < 0.0001$ for weeks 2, 4, 8, and ** $P = 0.019$ for week 12), and showed a reactive increase of platelet counts through weeks 1–4.




Figure 4. *ITPA* rs1127354 genotypes and reduction of platelet counts at week 4 of PEG-IFN/RBV therapy. The percentage of patients with platelet count reduction of >50 ($10^9/l$) (black bar), $30-50$ ($10^9/l$) (gray bar) and <30 ($10^9/l$) (white bar) at week 4 is shown for rs1127354 genotypes. The incidence of platelet count reduction of >50 and <30 was significantly lower in patients with the rs1127354 genotypes CC compared with AA/CA genotypes: 12 versus 35%, $P < 0.0001$, and 69 versus 31%, $P < 0.0001$, respectively.

In this study, two SNPs, rs11697186 and rs6139030, which were within and around *DDRGK1* gene on chromosome 20, were strongly associated with thrombocytopenia as well as

with Hb reduction at week 4. In clinical practice, the positive predictive value and negative predictive value by rs11697186 genotypes were 66.5 and 69.4% for thrombocytopenia, as well as 97.2 and 45% for RBV-induced anemia at week 4. As previously reported (22,26), a functional SNP (rs1127354) in the *ITPA* locus, which is in strong LD with rs11697186, was the most significant SNP associated with RBV-induced anemia and, in this study, IFN-induced thrombocytopenia in Japanese genetic populations. Note that severe Hb decline, which is mainly found in *ITPA*-CC patients, was inversely correlated with platelet reduction. This would contribute to an association between severe anemia and relative reactive increase of platelet count in this population, which attenuated the IFN effect on the platelet count. Our data supported a previous report which described that the current use of RBV, inducing severe anemia, might blunt the thrombocytopenic effect of IFNs as a result of reactive increase of platelet counts (27).

A previous paper showed hematological and bone marrow effects of RBV in rhesus monkeys (28). Hb values decreased significantly during RBV administration due to dose-related erythroid hypoplasia in bone marrow and returned to normal following withdrawal. On the other hand, increase of the platelet count occurred in both low- and high-dose treatment groups during RBV administration, with a fall of the platelet count to normal after drug withdrawal. The effect on platelet count was clearly dose related, with maximum counts rising to twice and three times above baseline levels in the low- and high-dose groups, respectively. This caused a significant increase of




Figure 5. Reactive increase of platelet counts through weeks 1–4. Box plots of reactive increase of platelet count through weeks 1–4 according to the degree of anemia at week 4 are shown for all patients (A) and a subgroup of patients with the rs1127354 genotypes CC (B). Patients with anemia (Hb reduction ≥ 3.0 g/dl) at week 4 had a significantly higher degree of reactive increase of platelet count than those without anemia ($P < 0.0001$). Box plots of reactive increase of platelet counts according to the rs1127354 genotype CC are shown for all patients (C) and a subgroup of patients without anemia (D) (Hb reduction < 3.0 g/dl) at week 4. Patients with the rs1127354 genotypes CC had a significantly high degree of reactive increase of platelet counts compared with those with genotypes AA/CA ($P < 0.0001$).

Table 4. Multivariate analysis of factors associated with reactive increase of platelets ≥ 20 ($10^9/l$) through weeks 1–4

	OR	95% CI	P-value
Baseline platelet counts	1.168	1.101–1.239	< 0.0001
ITPA AA/CA	0.379	0.168–0.856	0.0196
Platelet reduction ≥ 30 ($10^9/l$) at week 4	0.051	0.021–0.120	< 0.0001
Hb reduction ≥ 3.0 g/dl at week 4	1.602	0.914–2.809	0.0996

the platelet count associated with increased numbers of megakaryocytes. Additionally, the sequence homology of thrombopoietin (TPO) and erythropoietin (EPO) may explain the synergy of the physiologic role of TPO and EPO in platelet production. When EPO is elevated, as in iron deficiency anemia, an amino acid sequence similar to TPO may increase the platelet count (29).

Another possibility is a direct association between *ITPA* SNPs or the related SNPs with a strong LD and IFN-induced thrombocytopenia. *DDRGL1* (DDRGL domain-containing protein 1) is a novel C53/LZAP-interacting protein. C53/LZAP (also named as Cdk5rap3) is a putative tumor suppressor that plays important roles in multiple cell signaling pathways, including DNA damage response and NF- κ B signaling (30); however, it remains largely unknown how the function of *DDRGL1* variants is regulated. Further studies are required to elucidate the possible association between *DDRGL1* variants and thrombocytopenia.

Multivariate analysis demonstrated that rs1127354 in the *ITPA* gene was independently associated with RBV-induced severe anemia and IFN-induced thrombocytopenia. This finding suggests that rs1127354 would be a useful marker to predict these hematological side effects by PEG-IFN/RBV therapy, indicating that genetic testing of *ITPA* variant might be applied to establish personalized dosages of PEG-IFN/RBV therapy. The rate of SVR tended to be higher in patients with *ITPA*-AA/CA genotype than those

with *ITPA*-CC in this population. This might reflect decreased treatment efficacy (higher relapse rate) due to dose reduction of RBV in patients with *ITPA*-CC genotype. Our recent paper also demonstrated that the incidence of early dose reduction was significantly higher in *ITPA*-major (CC) patients as expected and, more importantly, that a significantly higher SVR rate was achieved in *ITPA*-hetero/minor (CA/AA) patients with HCV non-1b or low viral load strains (31) and in a subset of Japanese patients with the favorable TT genotype at rs8099917 of *IL28B* (32). Taken together, our results indicate that the *ITPA* minor variant A is not only a protective allele against PEG-IFN and RBV treatment-associated anemia in Japanese population, but also a significant predictor of SVR in certain HCV strains that show good response to IFN. The possible mechanism of protection against RBV-induced hemolysis is that ITP deficiency or low-activity variants (*ITPA* minor variant A) in turn lead to the accumulation of ITP in red blood cells (33,34), and the ITP confers protection against RBV-induced ATP reduction by substituting for erythrocyte GTP (25). On the other hand, half of the *ITPA*-major (CC) patients did not develop a significant Hb decline. This finding suggests other low-frequency *ITPA* variants or SNPs in other enzymes that are involved in erythrocyte purine nucleoside metabolism.

In Japan, the older HCV-infected patients developing liver fibrosis have been prevalent (mean age 62 years) (9). Thrombocytopenia by PEG-IFN/RBV therapy could lead to poor treatment efficiency among such Japanese patients with LC due to the initial or early dose reduction of PEG-IFN. In fact, $\sim 40\%$ of such population in this study had the initial dose reduction of PEG-IFN, resulting in a low SVR rate. Splenectomy or embolization of the splenic artery might be one of the options to increase the SVR rate, but a sufficient treatment outcome had not been obtained at present (35). Based on the recently accumulated SNP data, if patients had favorable *IL28B* genotype and *ITPA*-CC (lower reduction of platelet counts), a standard dose of PEG-IFN might be available for

the patients with lower platelet counts and the SVR rate might be increased due to sufficient dose of PEG-IFN.

Several STAT-C agents (specifically targeted antiviral therapies for hepatitis C) are being tested for clinical efficacy against hepatitis C (12,13,15,16). Most experts believe that when new drugs are approved to treat hepatitis C, they will be used in combination with PEG-IFN and RBV. Moreover, recent clinical trials, including NS3 protease inhibitors, have shown that PEG-IFN plus RBV would be necessary to achieve optimal treatment responses (12,13). Our present results may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN and RBV dosing to minimize drug-induced adverse events and for further optimization of clinical anti-HCV chemotherapeutics.

MATERIALS AND METHODS

Patients

From April 2007 to April 2010, samples were obtained from 303 patients with chronic HCV (genotype 1) infection who were treated at 14 multi-center hospitals (liver units with hepatologists) throughout Japan. Each patient was treated with PEG-IFN- α 2b (1.5 μ g/kg body weight, subcutaneously once a week) or PEG-IFN- α 2a (180 μ g once a week) plus RBV (600–1000 mg daily according to body weight) for 48 weeks. Treatment duration was extended in some patients up to 72 weeks, according to the physicians' preferences. The dose of PEG-IFN or RBV was reduced according to the recommendations on the package inserts or the clinical conditions of the individual patients. EPO or other growth factors were not given. Written informed consent was obtained from each patient and the study protocol conformed to the ethics guidelines of the Declaration of Helsinki and was approved by the institutional ethics review committees. HBsAg-positive and/or anti-HIV-positive patients were excluded from this study.

In the following stage of replication study, SNP genotyping in an independent set of 391 Japanese HCV patients treated with PEG-IFN plus RBV treatment was completed using the DigiTag2 or TaqMan assay (ABI) following the manufacturer's protocol. The characteristics of patients for each GWAS stage and replication stage are summarized in Table 1.

SNP genotyping and data cleaning

In the GWAS stage, we genotyped 303 Japanese HCV patients with and without the decrease of platelet counts from baseline to week 4 of PEG-IFN/RBV treatment [107 patients with a decrease of >30 ($10^9/l$) in platelet counts and 196 patients without a decrease of >30 ($10^9/l$) in platelet counts], using the Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's instructions. The cut-off value was calculated to maximize the difference, which was also close to the median change. The average overall call rate of patients with and without the decrease of PLT reached 98.69 and 98.72%, respectively. We then applied the following thresholds for SNP QC in data cleaning: SNP call rate $\geq 95\%$ for all samples, MAF $\geq 1\%$ for all samples. A total of 595 052 SNPs on autosomal chromosomes passed the QC filters and were used for association analysis. All cluster

plots of SNPs showing $P < 0.0001$ in association analyses by comparing allele frequencies in both groups with and without the decrease of PLT were checked by visual inspection, and SNPs with ambiguous genotype calls were excluded.

In the following stage of the replication study and high-density association mapping, we selected 23 tag SNPs from the 44.7 kb region, including *DDRGK1* gene and *ITPA* gene by analyzing LD and haplotype structure based on the HapMap data of Japanese, using the Haploview software. Of these tag SNPs, rs1127354 within the *ITPA* gene, which was associated with RBV-induced anemia (22), was included; however, rs7270101 was excluded because recent papers studying Japanese patients showed no variants in rs7270101 (26,31,32). The SNP genotyping in an independent set of 391 Japanese HCV patients with and without quantitative change in PLT levels from baseline to week 4 of PEG-IFN/RBV treatment (175 patients with quantitative change in PLT and 216 patients without quantitative change in PLT) was completed using the DigiTag2 assay (36). Twenty-two of the 23 SNPs were successfully analyzed and were used for SNP genotyping and data cleaning. All 22 SNPs in the replication study cleared HWE P -value > 0.001 .

Based on the above SNPs data obtained from 303 Japanese HCV patients, using the Affymetrix Genome-Wide Human SNP Array 6.0, we also performed GWAS between 94 patients with a quantitative change of >3 g of reduction in Hb and 209 patients without quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment. SNP genotyping in an independent set of 391 Japanese HCV patients with and without quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment (137 patients with quantitative change in Hb and 254 patients without quantitative change in Hb) was also completed using the DigiTag2 assay (36). Twenty-two of the 23 SNPs were successfully analyzed and were used for SNP genotyping and data cleaning.

An application of the Cochran–Armitage test on all the SNPs showed the genetic inflation factor $\lambda = 1.000$ for thrombocytopenia and $\lambda = 1.006$ for anemia in the GWAS stage (Supplementary Material, Figs S1 and S2). In addition, principal component analysis was performed in 303 samples for the GWAS stage together with the HapMap samples (CEU, YRI, CHB and JPT) (Supplementary Material, Fig. S3). These results implied that the effect of population stratification was negligible, except one sample, which was excluded from further analysis.

Laboratory and histological tests

Blood samples were obtained at baseline, 1, 2, 4, 8 and 12 weeks after the start of therapy and for hematologic tests after the start of therapy and for hematologic tests, blood chemistry and HCV-RNA. Genetic polymorphism in the *IL28B* gene (rs8099917) was determined using the ABI TaqMan assay (Applied Biosystems, Carlsbad, CA, USA). Fibrosis was evaluated on a scale of 0–4 according to the METAVIR scoring system. The SVR was defined as an undetectable HCV-RNA level by qualitative PCR with a lower detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems, CA, USA) or by Cobas Ampliprep/Cobas TaqMan assay (CAP/CTM) with a lower detection limit of

15 IU/ml (Roche Diagnostic Systems) 24 weeks after the completion of therapy.

Statistical analysis

The observed association between an SNP and the decrease of platelets/quantitative change in Hb levels with response to PEG-IFN plus RBV treatment was assessed by χ^2 test with a two-by-two contingency table in three genetic models: allele frequency model, dominant-effect model and recessive-effect model. SNPs on chromosome X were removed because gender was not matched between groups with and without the decrease of PLT and quantitative change in Hb levels. A total of 595 052 SNPs passed the quality control filters in the GWAS stage; therefore, significance levels after Bonferroni correction for multiple testing were $P = 8.40 \times 10^{-8}$ (0.05/595052) in the GWAS stage and $P = 2.27 \times 10^{-3}$ (0.05/22) in the replication stage.

The association between an SNP of the *ITPA* gene (rs1127354) and the incidence of platelet reduction at week 4 was analyzed by Fisher's exact test. The association between *ITPA* polymorphisms and the degree of reduction in platelet counts and Hb levels at each time point during therapy were analyzed by Mann-Whitney *U* test. Multivariable regression analysis was used to analyze the factors associated with *ITPA*, the rs1127354 genotype, factors associated with platelet count reductions and factors associated with the reactive increase in platelet counts. IBM-SPSS software v.15.0 (SPSS, Inc., Chicago, IL, USA) was used for these analyses.

Possible heterogeneity in allele frequencies at rs1127354 was assessed by Tarone's test. The association between the SNP and thrombocytopenia/anemia were analyzed by the Cochran-Mantel-Haenszel test. Both analyses were performed using the R (version 2.9.0) software (Supplementary Material, Table S3).

AUTHORS' CONTRIBUTIONS

Drafting of the paper, statistical analysis and approval of the final draft submitted: M.M.; drafting of the paper, statistical analysis, collecting samples and clinical data and approval of the final draft submitted: Y.T. and M.K.; statistical analysis and approval of the final draft submitted: N.N., M.S. and K.T.; collecting samples and clinical data and approval of the final draft submitted: K.M., N.S., N.E., H.Y., S.N., K.H., S.H., Y.I., E.T., S.M., M.H., Y.H., F.S., S.K. and N.I.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENTS

This study is based on 14 multi-center hospitals throughout Japan: Hokkaido area (Hokkaido University Hospital), Kanto area (Saitama University Hospital; Konodai Hospital; Musashino Red Cross Hospital; Tokyo Medical and Dental University Hospital; Yamanashi University Hospital), Koshin area (Shinshu University Hospital; Kanazawa University

Hospital), Tokai area (Nagoya City University Hospital), Kinki area (Kyoto Prefectural University of Medicine Hospital; Hyogo College of Medicine Hospital), Chugoku/Shikoku area (Ehime University Hospital; Kawasaki Medical College Hospital) and Kyushu area (National Nagasaki Medical Center). We thank Ms Yasuka Uehara-Shibata, Yuko Ogasawara-Hirano, Yoshimi Ishibashi, Natsumi Baba and Megumi Yamaoka-Sageshima (Tokyo University) for technical assistance. We also thank Dr Masaaki Korenaga (Kawasaki), Dr Akihiro Matsumoto (Shinshu), Dr Kayoko Naiki (Saitama), Dr Takeshi Nishimura (Kyoto), Dr Hirayuki Enomoto (Hyogo), Dr Minako Nakagawa (Tokyo Medical and Dental University) and Ochanomizu Liver Conference Study Group for collecting samples, and Dr Mamoru Watanabe (Tokyo Medical and Dental University) and Dr Moriichi Onji (Ehime University) for their advice throughout the study.

Conflict of Interest statement. Y.T., E.T. and S.K. are currently conducting research sponsored by Merck Sharp & Dohme, Corp. and Chugai Pharmaceutical Co. Ltd. The other co-authors have no conflict of interest.

FUNDING

This study was supported by a grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan (H22-kannen-005), and the Ministry of Education, Culture, Sports, Science, and Technology.

REFERENCES

1. Global Burden of Hepatitis C Working Group (2004) Global burden of disease (GBD) for hepatitis C. *J. Clin. Pharmacol.*, **44**, 20–29.
2. Shiratori, Y., Shiina, S., Imamura, M., Kato, N., Kanai, F., Okudaira, T., Teratani, T., Tohgo, G., Toda, N., Ohashi, M. *et al.* (1995) Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. *Hepatology*, **22**, 1027–1033.
3. Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M., Fujiyama, S., Nishiguchi, S., Ishibashi, H., Yamada, G., Yokosuka, O., Shiratori, Y. *et al.* (2004) Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. *Gut*, **53**, 425–430.
4. George, S.L., Bacon, B.R., Brunt, E.M., Mihindukulasuriya, K.L., Hoffmann, J. and Di Bisceglie, A.M. (2009) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology*, **49**, 729–738.
5. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncalves, F.L. Jr, Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D. *et al.* (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.*, **347**, 975–982.
6. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M. and Albrecht, J.K. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*, **358**, 958–965.
7. Hadziyannis, S.J., Sette, H. Jr, Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr, Bernstein, D., Rizzetto, M. *et al.* (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann. Intern. Med.*, **140**, 346–355.
8. Hiramatsu, N., Oze, T., Tsuda, N., Kurashige, N., Koga, K., Toyama, T., Yasumaru, M., Kanto, T., Takehara, T., Kasahara, A. *et al.* (2006) Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? *Hepatol. Res.*, **35**, 185–189.
9. Iwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe, T., Takaguchi, K., Hashimoto, N., Kobatake, T. *et al.* (2006) Limitation of

- combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. *Hepatology*, **43**, 54–63.
10. Sezaki, H., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Kobayashi, M., Suzuki, Y., Arase, Y., Ikeda, K., Miyakawa, Y. *et al.* (2009) An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. *Intervirology*, **52**, 43–48.
 11. Bruno, R., Sacchi, P., Maiocchi, L., Patrino, S. and Filice, G. (2006) Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. *Dig. Liver Dis.*, **38**, 363–373.
 12. Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.P., Bourliere, M., Gharakhanian, S., Bengtsson, L. *et al.* (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N. Engl. J. Med.*, **360**, 1839–1850.
 13. McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J. and Muir, A.J. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N. Engl. J. Med.*, **360**, 1827–1838.
 14. Suzuki, F., Akuta, N., Suzuki, Y., Sezaki, H., Yatsuji, H., Kawamura, Y., Hosaka, T., Kobayashi, M., Arase, Y., Ikeda, K. *et al.* (2009) Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. *Hepatol. Res.*, **39**, 1056–1063.
 15. Sakamoto, N. and Watanabe, M. (2009) New therapeutic approaches to hepatitis C virus. *J. Gastroenterol.*, **44**, 643–649.
 16. Afdhal, N.H., McHutchison, J.G., Zeuzem, S., Mangia, A., Pawlowsky, J.M., Murray, J.S., Shianna, K.V., Tanaka, Y., Thomas, D.L., Booth, D.R. *et al.* (2010) Hepatitis C pharmacogenetics: state of the art in 2010. *Hepatology*, **53**, 336–345.
 17. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S. *et al.* (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat. Genet.*, **41**, 1105–1109.
 18. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., Qiu, P., Bertelsen, A.H., Muir, A.J. *et al.* (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*, **461**, 399–401.
 19. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., Spengler, U., Dore, G.J., Powell, E. *et al.* (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat. Genet.*, **41**, 1100–1104.
 20. Thomas, D.L., Thio, C.L., Martin, M.P., Qi, Y., Ge, D., O’Huigin, C., Kidd, J., Kidd, K., Khakoo, S.I., Alexander, G. *et al.* (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature*, **461**, 798–801.
 21. Tanaka, Y., Nishida, N., Sugiyama, M., Tokunaga, K. and Mizokami, M. (2010) lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. *Hepatol. Res.*, **40**, 449–460.
 22. Fellay, J., Thompson, A.J., Ge, D., Gumbs, C.E., Urban, T.J., Shianna, K.V., Little, L.D., Qiu, P., Bertelsen, A.H., Watson, M. *et al.* (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature*, **464**, 405–408.
 23. Afdhal, N., McHutchison, J., Brown, R., Jacobson, I., Manns, M., Poordad, F., Weksler, B. and Esteban, R. (2008) Thrombocytopenia associated with chronic liver disease. *J. Hepatol.*, **48**, 1000–1007.
 24. Wazny, L.D. and Ariano, R.E. (2000) Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. *Pharmacotherapy*, **20**, 292–307.
 25. Hitomi, Y., Cirulli, E.T., Fellay, J., McHutchison, J.G., Thompson, A.J., Gumbs, C.E., Shianna, K.V., Urban, T.J. and Goldstein, D.B. (2011) Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. *Gastroenterology*, **140**, 1314–1321.
 26. Ochi, H., Maekawa, T., Abe, H., Hayashida, Y., Nakano, R., Kubo, M., Tsunoda, T., Hayes, C.N., Kumada, H., Nakamura, Y. *et al.* (2010) ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy—a genome-wide study of Japanese HCV virus patients. *Gastroenterology*, **139**, 1190–1197.
 27. Ong, J.P. and Younossi, Z.M. (2004) Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. *Cleve. Clin. J. Med.*, **71** (Suppl. 3), S17–S21.
 28. Canonico, P.G., Castello, M.D., Cosgriff, T.M., Donovan, J.C., Ross, P.E., Spears, C.T. and Stephen, E.L. (1984) Hematological and bone marrow effects of ribavirin in rhesus monkeys. *Toxicol. Appl. Pharmacol.*, **74**, 163–172.
 29. Akan, H., Guven, N., Aydogdu, I., Arat, M., Beksac, M. and Dalva, K. (2000) Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. *Acta Haematol.*, **103**, 152–156.
 30. Wu, J., Lei, G., Mei, M., Tang, Y. and Li, H. (2010) A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing protein 1 (DDRGK1) and modulates NF-kappaB signaling. *J. Biol. Chem.*, **285**, 15126–15136.
 31. Sakamoto, N., Tanaka, Y., Nakagawa, M., Yatsuhashi, H., Nishiguchi, S., Enomoto, N., Azuma, S., Nishimura-Sakurai, Y., Kakinuma, S., Nishida, N. *et al.* (2010) ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol. Res.*, **40**, 1063–1071.
 32. Kurosaki, M., Tanaka, Y., Tanaka, K., Suzuki, Y., Hoshioka, Y., Tamaki, N., Kato, T. and Yasui, Y. (2011) Analysis of the correlations between genetic polymorphisms of the ITPA gene and hemolytic anemia or outcome after treatment with pegylated-interferon and ribavirin in genotype 1b chronic hepatitis C. *Antivir. Ther.*, in press.
 33. Shipkova, M., Lorenz, K., Oellerich, M., Wieland, E. and von Ahsen, N. (2006) Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. *Clin. Chem.*, **52**, 240–247.
 34. Fraser, J.H., Meyers, H., Henderson, J.F., Brox, L.W. and McCoy, E.E. (1975) Individual variation in inosine triphosphate accumulation in human erythrocytes. *Clin. Biochem.*, **8**, 353–364.
 35. Kumada, H., Okanoue, T., Onji, M., Moriwaki, H., Izumi, N., Tanaka, E., Chayama, K., Sakisaka, S., Takehara, T., Oketani, M. *et al.* (2010) Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. *Hepatol. Res.*, **40**, 8–13.
 36. Nishida, N., Tanabe, T., Takasu, M., Suyama, A. and Tokunaga, K. (2007) Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. *Anal. Biochem.*, **364**, 78–85.

A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan

Atsunori Kusakabe · Yasuhito Tanaka · Manami Inoue · Fuat Kurbanov · Kanako Tatematsu · Shunsuke Nojiri · Takashi Joh · Shoichiro Tsugane · Masashi Mizokami

Received: 20 May 2010 / Accepted: 2 August 2010 / Published online: 7 September 2010
© Springer 2010

Abstract

Background There have only been a few prospective studies investigating risk factors associated with the development of hepatocellular carcinoma (HCC) among chronic hepatitis B patients all over the world, and no study has been conducted in Japanese population.

Methods A population-based cohort consisting of 19393 subjects (middle aged or older) with over 13 years' follow-up was investigated in Japan.

Results Of 19393 subjects, 479 had hepatitis B virus (HBV) mono-infection (2.5%). During the 245923 person-years' follow-up (average follow-up period 12.7 years), 13

cases of newly diagnosed HCC were documented in the HBV mono-infected group. Several factors at baseline (male, smoking, alanine aminotransferase, the positivity of HBe antigen and HB core-related antigen, the proportion of HBV DNA ≥ 5 log copies/mL, T1753V mutation, and A1762T/G1764A double mutation) were significantly associated with HCC among HBV mono-infected subjects. Multivariate-adjusted Cox hazard model showed that A1762T/G1764A (hazard ratio 7.05 [95% confidence interval (CI) 1.03–48.12, $P = 0.046$]) was the only independent risk factor for the development of HCC. Kaplan–Meier method also showed that the probability of HCC occurrence-free was significantly lower in HBV mono-infected subjects with A1762T/G1764A double mutation than those without these mutations.

Conclusion HBV mono-infected subjects with A1762T/G1764A double mutation could be at high risk of HCC development during the natural course of HBV infection.

Keywords Hepatitis B virus · Hepatocellular carcinoma · Risk factor · Japan

This article is authored in cooperation with the JPHC Study Group, members of which are listed in the Appendix.

The online version of the editorial referring to this article can be found under doi:10.1007/s00535-010-0314-5.

A. Kusakabe · S. Nojiri · T. Joh
Department of Gastroenterology and Metabolism,
Nagoya City University Graduate School of Medical Sciences,
Nagoya, Japan

Y. Tanaka (✉) · F. Kurbanov · K. Tatematsu
Department of Virology and Liver Unit,
Nagoya City University Graduate School of Medical Sciences,
Kawasumi, Mizuho, Nagoya 467-8601, Japan
e-mail: ytanaka@med.nagoya-cu.ac.jp

M. Inoue · S. Tsugane
Epidemiology and Prevention Division,
Research Center for Cancer Prevention and Screening,
National Cancer Center, Tokyo, Japan

M. Mizokami
The Research Center for Hepatitis and Immunology,
National Center for Global Health and Medicine,
Ichikawa, Japan

Introduction

Hepatitis B virus (HBV) infection is one of the most common viral infections among humans and chronic hepatitis B (CHB) infection affects 350–400 million people worldwide [1]. Furthermore, CHB infection is the most serious etiology of hepatocellular carcinoma (HCC) in Asia [2], and the second most in Japan [3]. In fact, it was reported that individuals who happened to have HBV chronic infections have higher risk of developing HCC than uninfected ones [2]. Hence, it is very important to identify the risk factors associated with the development of HCC among CHB patients.